3
Clinical Trials associated with Cytokine-induced killer cell therapy (Alliancells-PuRui Biosciences) / SuspendedNot ApplicableIIT Prospective and Exploratory Clinical Study of CIK Cells Combined with Targeted Therapy for Advanced Renal Cancer
/ SuspendedNot ApplicableIIT Prospective and Exploratory Clinical Study for Concurrent Radiochemotherapy and CIK Cells in the treatment of the First Diagnosis of Metastatic Nasopharyngeal Carcinoma
Phase 1 Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection
Cytokine-induced killer (CIK) cells are a heterogeneous subset of ex-vivo expanded T lymphocytes which present a mixed T-NK phenotype and are endowed with a major histocompatibility complex-unrestricted antitumor activity. Radical surgery is a good therapy for patients with solid tumor.However, tumor relapse is still a risk for those patients. Our hypothsis is that cytokine induced killer cells maybe decrease the recurrence rate. The purpose of this study is to evaluate the safety and tolerability of cord blood-derived cytokine induced killer cells in patients with solid tumor following radical resection.
100 Clinical Results associated with Cytokine-induced killer cell therapy (Alliancells-PuRui Biosciences)
100 Translational Medicine associated with Cytokine-induced killer cell therapy (Alliancells-PuRui Biosciences)
100 Patents (Medical) associated with Cytokine-induced killer cell therapy (Alliancells-PuRui Biosciences)
100 Deals associated with Cytokine-induced killer cell therapy (Alliancells-PuRui Biosciences)